Targeting the Bundibugyo Strain with Obeldesivir
The World Health Organization (WHO) has launched the EBO-PEP clinical trial, the first to test the antiviral drug obeldesivir as a post-exposure treatment for the Bundibugyo strain of the Ebola virus. Developed by the U.S. pharmaceutical firm Gilead Sciences, the oral drug aims to prevent high-risk contacts of confirmed cases from developing the disease.
The study focuses on individuals who have had direct contact with confirmed cases within the previous five days but remain asymptomatic. Researchers aim to recruit nearly 1,000 participants aged 12 and older. Each will undergo daily monitoring for 21 days, followed by a final visit at 42 days. Operations are currently underway at PEP centres in Bunia and Rwampara, Ituri province, adjacent to the Ebola treatment centres operated by the NGO Alliance for International Medical Action (ALIMA).
Security and Surveillance Hurdles in Ituri
The Bundibugyo strain remains a threat in the Democratic Republic of Congo. Official figures record more than 1,960 infections and over 700 deaths. However, WHO emergencies chief Chikwe Ihekweazu warned that the true scale of the outbreak may be at least two to four times higher than official reports suggest.
During a briefing in Geneva, Ihekweazu noted that 80% of new cases are identified outside of known contact lists, suggesting “unknown chains of transmission.” The crisis is further compounded by the security environment in Ituri, a mineral-rich north-eastern province plagued by armed groups. Consequently, many patients are succumbing to the virus without ever reaching a medical facility.
Expanding the Search for Effective Therapies
There are currently no approved vaccines or treatments for the Bundibugyo species of Ebola. Beyond the obeldesivir trial, a separate study began on July 2 to evaluate two other potential treatments: the monoclonal antibody MBP134 and the antiviral drug remdesivir, tested both individually and in combination.
The WHO expects this to be a long-term effort. Officials indicated that trials may continue into next year and require more than 1,000 patients to yield definitive answers. Ultimately, the WHO emphasizes that success depends on the ability to reach high-risk contacts before they transition from exposure to active disease.
Fact Sheet: Ebola Outbreak Response
- Primary Trial: EBO-PEP (testing obeldesivir).
- Secondary Trial: Evaluating MBP134 and remdesivir.
- Target Population: Asymptomatic individuals exposed to confirmed cases within the last five days.
- Primary Geographic Focus: Ituri province, DRC.
- Transmission Note: Ebola spreads through close contact and infected bodily fluids.
Worth a look